Treatment News

Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

3.0 from 22 votes
Wednesday, March 21, 2018

NEW YORK - Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced that Mark R. Baker, Chief Executive Officer, will present at the 17th Annual Needham Healthcare Conference in New York City on Tuesday, March 27, 2018 at 3:00 p.m. Eastern Daylight Time.

A live webcast of the presentation will be available in the Media Center of the Progenics website, To ensure a timely connection, users should register at least 15 minutes prior to the scheduled start. An archive of the event will be available for 90 days.

About Progenics
Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA®, 1095, and PSMA TTC), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis technology. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.

Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit Information on or accessed through our website or social media sites is not included in the company's SEC filings.

Melissa Downs
Investor Relations
(646) 975-2533

Source: Progenics Pharmaceuticals, Inc.
3.0 from 22 votes
Free Newsletter
Trending News